Lv5
1130 积分 2025-04-14 加入
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
12天前
已完结
Esophageal Cancer
17天前
已完结
The changing therapeutic landscape of small-cell lung cancer
1个月前
已完结
成人肺功能检查技术进展及临床应用推荐指南(2025版)
1个月前
已完结
中国常规肺功能检查基层指南（2024年）
1个月前
已完结
Regulation of immune checkpoint molecules in cancer immune evasion and therapy
1个月前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial
1个月前
已完结
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
2个月前
已完结
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)
2个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
皖公网安备34019202002308
